2 142

Cited 0 times in

Efficacy of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane Versus a Covered Metal Stent for Malignant Biliary Obstruction: A Prospective Comparative Study

Authors
 Sung Ill Jang  ;  Jie-Hyun Kim  ;  Dong Ki Lee  ;  Sang-Heum Park  ;  Im Hee Shin  ;  Jimin Han  ;  Ho Gak Kim  ;  Se Joon Lee  ;  Kwangwon Rhee  ;  Jung Whan You 
Citation
 Digestive Diseases and Sciences, Vol.58(3) : 865-871, 2013 
Journal Title
 Digestive Diseases and Sciences 
ISSN
 0163-2116 
Issue Date
2013
Abstract
BACKGROUND: The placement of a self-expandable metallic stent (SEMS) is a widely used nonsurgical treatment method in patients with unresectable malignant biliary obstructions but SEMS is susceptible to occlusion by tumor ingrowth or overgrowth. AIM: The efficacy and safety of a metallic stent covered with a paclitaxel-incorporated membrane (MSCPM) in which paclitaxel provided an antitumoral effect was compared prospectively with those of a covered metal stent (CMS) in patients with malignant biliary obstructions. METHODS: Patients with unresectable distal malignant biliary obstructions (n = 106) were prospectively enrolled in this study at multiple treatment centers. A MSCPM was inserted endoscopically in 60 patients, and a CMS was inserted in 46 patients. Patients underwent systemic chemotherapy regimens alternatively according to disease characteristics. RESULTS: The two groups did not differ significantly in mean age, male to female ratio, or mean follow-up period. Stent occlusion due to tumor ingrowth occurred in 12 patients who received MSCPMs and in eight patients who received CMSs. Stent patency and survival time did not differ significantly between the two groups (p = 0.116, 0.981). Chemotherapy had no influence on stent patency, but gemcitabine-based chemotherapy was a significant prognostic factor for survival time (p = 0.012). Complications, including cholangitis and pancreatitis, were found to be acceptable in both groups. CONCLUSIONS: Although the use of a MSCPM produced no significant differences in stent patency or patient survival in patients with malignant biliary obstructions compared with the use of a CMS, this study demonstrated that MSCPM can be used safely in humans.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/86688
DOI
10.1007/s10620-012-2472-1
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Biochemistry & Molecular Biology (생화학-분자생물학교실)
Yonsei Authors
김지현(Kim, Ji Hyun) ; 유정환(You, Jung Whan) ; 이동기(Lee, Dong Ki) ; 이세준(Lee, Se Joon) ; 장성일(Jang, Sung Ill)
사서에게 알리기
  feedback
Full Text
http://link.springer.com/article/10.1007%2Fs10620-012-2472-1
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse